<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="abstract"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">J Int AIDS Soc</journal-id><journal-id journal-id-type="iso-abbrev">J Int AIDS Soc</journal-id><journal-id journal-id-type="publisher-id">JIAS</journal-id><journal-title-group><journal-title>Journal of the International AIDS Society</journal-title></journal-title-group><issn pub-type="epub">1758-2652</issn><publisher><publisher-name>International AIDS Society</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">25394079</article-id><article-id pub-id-type="pmc">4224823</article-id><article-id pub-id-type="publisher-id">19572</article-id><article-id pub-id-type="doi">10.7448/IAS.17.4.19572</article-id><article-categories><subj-group subj-group-type="heading"><subject>Poster Sessions &#x02013; Abstract P040</subject></subj-group></article-categories><title-group><article-title>Acceptance rate of clinical study endpoints and adequacy of source documentation: experience from clinical study endpoint review in NEAT001/ANRS143</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Berenguer</surname><given-names>Juan</given-names></name><xref ref-type="aff" rid="AF0001_19572">1</xref></contrib><contrib contrib-type="author"><name><surname>Wit</surname><given-names>Ferdinand</given-names></name><xref ref-type="aff" rid="AF0002_19572">2</xref></contrib><contrib contrib-type="author"><name><surname>Jansson</surname><given-names>Per O</given-names></name><xref ref-type="aff" rid="AF0003_19572">3</xref></contrib><contrib contrib-type="author"><name><surname>Schwimmer</surname><given-names>Christine</given-names></name><xref ref-type="aff" rid="AF0004_19572">4</xref></contrib><contrib contrib-type="author"><name><surname>Kowalska</surname><given-names>Justyna D</given-names></name><xref ref-type="aff" rid="AF0005_19572">5</xref></contrib><contrib contrib-type="author"><name><surname>Saillard</surname><given-names>Juliette</given-names></name><xref ref-type="aff" rid="AF0006_19572">6</xref></contrib><contrib contrib-type="author"><name><surname>Diallo</surname><given-names>Alpha</given-names></name><xref ref-type="aff" rid="AF0006_19572">6</xref></contrib><contrib contrib-type="author"><name><surname>Pozniak</surname><given-names>Anton L</given-names></name><xref ref-type="aff" rid="AF0007_19572">7</xref></contrib><contrib contrib-type="author"><name><surname>Raffi</surname><given-names>Fran&#x000e7;ois</given-names></name><xref ref-type="aff" rid="AF0008_19572">8</xref></contrib><contrib contrib-type="author"><name><surname>Grarup</surname><given-names>Jesper</given-names></name><xref ref-type="aff" rid="AF0003_19572">3</xref></contrib></contrib-group><aff id="AF0001_19572"><label>1</label>Hospital General Universitario Gregorio Mara&#x000f1;on, ID, Madrid, Spain</aff><aff id="AF0002_19572"><label>2</label>Department of Global Health, Amsterdam Institute for Global Health and Development, AMC, Amsterdam, Netherlands</aff><aff id="AF0003_19572"><label>3</label>CHIP, Department of Infectious Disease and Rheumatology, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark</aff><aff id="AF0004_19572"><label>4</label>INSERM, U897, Bordeaux, France</aff><aff id="AF0005_19572"><label>5</label>Wojewodzki Szpital Zakazny, ID, Warszawa, Poland</aff><aff id="AF0006_19572"><label>6</label>ANRS, Service de recherches cliniques et th&#x000e9;rapeutiques, Paris, France</aff><aff id="AF0007_19572"><label>7</label>Chelsea and Westminster Hospital, NHS Foundation Trust, ID, London, UK</aff><aff id="AF0008_19572"><label>8</label>University Hospital, ID, Nantes, France</aff><pub-date pub-type="epub"><day>02</day><month>11</month><year>2014</year></pub-date><pub-date pub-type="collection"><year>2014</year></pub-date><volume>17</volume><issue>4Suppl 3</issue><elocation-id content-type="doi">19572</elocation-id><permissions><copyright-statement>&#x000a9; 2014 Berenguer J et al; licensee International AIDS Society</copyright-statement><copyright-year>2014</copyright-year><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/3.0/"><license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><abstract><sec id="st1_19572"><title>Introduction</title><p>
NEAT001/ANRS143 was an open-label, randomized, non-inferiority study comparing raltegravir+darunavir/r(RGV+DRV/r) vs. tenofovir/emtricitabine+darunavir/r (TDF/FTC+DRV/r) in HIV-infected antiretroviral na&#x000ef;ve adults. Primary efficacy outcome was a composite of virological and clinical events by week 96.</p></sec><sec id="st2_19572"><title>Materials and Methods</title><p>
Clinical trial units collected and translated supporting documentation (SD) related to the investigator-reported events. A coordinator checked events and SD for consistency and completeness. The Endpoint Review Committee (ERC) determined if clinical events met pre-defined diagnostic criteria in categories &#x0201c;confirmed&#x0201d; or &#x0201c;probable&#x0201d;. The ERC of 12 experienced, independent clinicians served in groups of three conducting individual reviews in writing, blinded to treatment arm. Differences of opinion were adjudicated in a second review by direct dialogue between reviewers. &#x0201c;Confirmed&#x0201d; events required adequate SD like laboratory, radiographic or pathology diagnostic reports. &#x0201c;Probable&#x0201d; events were typically based on clinical criteria.</p></sec><sec id="st3_19572"><title>Results</title><p>Of the 164 serious and 3,964 adverse events reported in the study, 133 qualified for endpoint review, for a total of 153 adjudications:</p><p>Sixty of 111 per protocol endpoints were confirmed (n=53) or probable (n=7), which equals an acceptance rate of 54%. In two confirmed cases, SD was partly adequate and evaluation uncertain. Of 51 rejected events, 13 had insufficient SD, two were recurrent events. The rate of rejected events was comparable between treatments with 41% rejected events in the RGV+DRV/r arm compared to 52% in the TDF/FTC+DRV/r arm. The IRIS acceptance rate was low (3 of 18), demonstrating the difference in perception of IRIS in daily patient management and the stricter protocol definition.</p></sec><sec id="st4_19572"><title>Conclusions</title><p>Blinded endpoint review prevented unacceptably high false positive event rates documenting that real-time ascertainment of clinical endpoints is crucial for appropriateness of the overall results. Non-confirmed events jeopardize the statistical power in this and probably all kinds of clinical studies. The rejection rate was not indicative of poor study conduct &#x02013; on the contrary over-reporting prevented missing events, which would have adversely impacted the trial. Adequacy of SD and investigator training on possible differences in event criteria in daily pragmatic clinical management compared to protocol defined criteria is essential.
</p></sec></abstract></article-meta></front><body><table-wrap id="T0001_19572" position="float"><label>Table 1</label><caption><p>Endpoint review results by type of endpoint</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="1" colspan="1"/><th align="center" rowspan="1" colspan="1">Clinical study endpoint</th><th align="center" rowspan="1" colspan="1">Clinical study endpoint</th><th align="center" rowspan="1" colspan="1">Clinical study endpoint</th><th align="center" rowspan="1" colspan="1">Clinical study endpoint</th><th align="center" rowspan="1" colspan="1">Clinical study endpoint</th><th align="center" rowspan="1" colspan="1">Clinical study endpoint</th><th align="center" rowspan="1" colspan="1">Rashes</th></tr><tr><th align="left" rowspan="1" colspan="1"/><th colspan="7" align="left" rowspan="1"><hr/></th></tr><tr><th align="left" rowspan="1" colspan="1"/><th align="center" rowspan="1" colspan="1">All</th><th align="center" rowspan="1" colspan="1">AIDS</th><th align="center" rowspan="1" colspan="1">Serious non-AIDS</th><th align="center" rowspan="1" colspan="1">IRIS</th><th align="center" rowspan="1" colspan="1">Clinical Grade 4 AE</th><th align="center" rowspan="1" colspan="1">Death</th><th align="center" rowspan="1" colspan="1">Rash</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Total reviewed events</td><td align="center" rowspan="1" colspan="1">111</td><td align="center" rowspan="1" colspan="1">24</td><td align="center" rowspan="1" colspan="1">35</td><td align="center" rowspan="1" colspan="1">18</td><td align="center" rowspan="1" colspan="1">29</td><td align="center" rowspan="1" colspan="1">5</td><td align="center" rowspan="1" colspan="1">42</td></tr><tr><td align="left" rowspan="1" colspan="1">Per Protocol Endpoints (confirmed + probable)</td><td align="center" rowspan="1" colspan="1">60</td><td align="center" rowspan="1" colspan="1">11</td><td align="center" rowspan="1" colspan="1">18</td><td align="center" rowspan="1" colspan="1">3</td><td align="center" rowspan="1" colspan="1">23</td><td align="center" rowspan="1" colspan="1">5</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Confirmed Events (for rashes: grade 2-4)</td><td align="center" rowspan="1" colspan="1">53</td><td align="center" rowspan="1" colspan="1">11</td><td align="center" rowspan="1" colspan="1">16</td><td align="center" rowspan="1" colspan="1">2</td><td align="center" rowspan="1" colspan="1">19</td><td align="center" rowspan="1" colspan="1">5</td><td align="center" rowspan="1" colspan="1">28</td></tr><tr><td align="left" rowspan="1" colspan="1">SD* adequate</td><td align="center" rowspan="1" colspan="1">42</td><td align="center" rowspan="1" colspan="1">10</td><td align="center" rowspan="1" colspan="1">11</td><td align="center" rowspan="1" colspan="1">1</td><td align="center" rowspan="1" colspan="1">16</td><td align="center" rowspan="1" colspan="1">4</td><td align="center" rowspan="1" colspan="1">6</td></tr><tr><td align="left" rowspan="1" colspan="1">SD* sufficiently/only partly adequate</td><td align="center" rowspan="1" colspan="1">10/1</td><td align="center" rowspan="1" colspan="1">1/0</td><td align="center" rowspan="1" colspan="1">5/0</td><td align="center" rowspan="1" colspan="1">0/1</td><td align="center" rowspan="1" colspan="1">3/0</td><td align="center" rowspan="1" colspan="1">1/0</td><td align="center" rowspan="1" colspan="1">19/3</td></tr><tr><td align="left" rowspan="1" colspan="1">Probable Events</td><td align="center" rowspan="1" colspan="1">7</td><td align="center" rowspan="1" colspan="1">0</td><td align="center" rowspan="1" colspan="1">2</td><td align="center" rowspan="1" colspan="1">15</td><td align="center" rowspan="1" colspan="1">4</td><td align="center" rowspan="1" colspan="1">0</td><td align="center" rowspan="1" colspan="1">-</td></tr><tr><td align="left" rowspan="1" colspan="1">SD* sufficiently/ only partly adequate</td><td align="center" rowspan="1" colspan="1">6/1</td><td align="center" rowspan="1" colspan="1">0/0</td><td align="center" rowspan="1" colspan="1">2/0</td><td align="center" rowspan="1" colspan="1">2</td><td align="center" rowspan="1" colspan="1">4/0</td><td align="center" rowspan="1" colspan="1">0/0</td><td align="center" rowspan="1" colspan="1">-/-</td></tr><tr><td align="left" rowspan="1" colspan="1">Rejected Events (for rashes: grade 1 or not a rash)</td><td align="center" rowspan="1" colspan="1">51</td><td align="center" rowspan="1" colspan="1">13</td><td align="center" rowspan="1" colspan="1">17</td><td align="center" rowspan="1" colspan="1">15</td><td align="center" rowspan="1" colspan="1">6</td><td align="center" rowspan="1" colspan="1">0</td><td align="center" rowspan="1" colspan="1">14</td></tr><tr><td align="left" rowspan="1" colspan="1">Not fulfil criteria, SD* adequate</td><td align="center" rowspan="1" colspan="1">17</td><td align="center" rowspan="1" colspan="1">3</td><td align="center" rowspan="1" colspan="1">9</td><td align="center" rowspan="1" colspan="1">2</td><td align="center" rowspan="1" colspan="1">3</td><td align="center" rowspan="1" colspan="1">0</td><td align="center" rowspan="1" colspan="1">4</td></tr><tr><td align="left" rowspan="1" colspan="1">Not fulfil criteria, SD* sufficiently adequate</td><td align="center" rowspan="1" colspan="1">21</td><td align="center" rowspan="1" colspan="1">8</td><td align="center" rowspan="1" colspan="1">3</td><td align="center" rowspan="1" colspan="1">8</td><td align="center" rowspan="1" colspan="1">2</td><td align="center" rowspan="1" colspan="1">0</td><td align="center" rowspan="1" colspan="1">5</td></tr><tr><td align="left" rowspan="1" colspan="1">Not fulfil criteria, SD* only partly adequate</td><td align="center" rowspan="1" colspan="1">13</td><td align="center" rowspan="1" colspan="1">2</td><td align="center" rowspan="1" colspan="1">5</td><td align="center" rowspan="1" colspan="1">5</td><td align="center" rowspan="1" colspan="1">1</td><td align="center" rowspan="1" colspan="1">0</td><td align="center" rowspan="1" colspan="1">5</td></tr></tbody></table></table-wrap></body></article>